Updated: DICE rolls on as lead oral IL-17 candidate meets proof-of-concept in PhI trial, sending shares higher
DICE Therapeutics is now moving forward on the next stage of clinical development for its IL-17 candidate, on the heels of touting a Phase I win. And investors are responding in kind.
DICE reported topline data Tuesday from a Phase I trial enrolling 104 patients — a mix of healthy volunteers and psoriasis patients — testing oral small molecule DC-806, an IL-17 antagonist, and generating safety and pharmacokinetic data. The study was conducted in three different parts: the Phase Ia testing a single ascending dose in 40 patients, a Phase Ib multiple ascending dose phase in 32 patients, and a Phase Ic proof-of-concept test in 32 patients with psoriasis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.